What is the price target for IDYA stock?
25 analysts have analysed IDYA and the average price target is 49.98 USD. This implies a price increase of 75.29% is expected in the next year compared to the current price of 28.512.
IDEAYA BIOSCIENCES INC (IDYA) Forecast, Price Target & Analyst Ratings
NASDAQ:IDYA • US45166A1025
Current stock price
28.512 USD
-0.53 (-1.82%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IDEAYA BIOSCIENCES INC (IDYA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.01
- Revenue Estimate
- 5.108M
Price Target Details & History
Consensus Price Target and Range
Mean target
$49.98
Upside
+ 75.29%
From current price of $28.51 to mean target of $49.98, Based on 25 analyst forecasts
Low
$31.31
Median
$50.49
High
$68.25
Price Target Revisions
1 Month
-3.48%
3 Months
-1.42%
Price Target Summary
25 Wall Street analysts provided a forecast for the next 12 months for IDYA. The average price target is 49.98 USD. This implies a price increase of 75.29% is expected in the next year compared to the current price of 28.512.
The average price target has been revised downward by 1.42% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.80%
IDYA was analyzed by 25 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about IDYA.
In the previous month the buy percentage consensus was at a similar level.
IDYA was analyzed by 25 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-14 | Guggenheim | Maintains | Buy -> Buy |
| 2026-04-14 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-04-14 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-04-14 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-04-14 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2026-03-31 | Wedbush | Reiterate | Outperform -> Outperform |
| 2026-02-19 | Citigroup | Maintains | Buy -> Buy |
| 2026-02-18 | Guggenheim | Reiterate | Buy -> Buy |
| 2026-02-18 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2026-02-18 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-01-21 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-06 | Truist Securities | Maintains | Buy -> Buy |
| 2025-11-24 | Truist Securities | Initiate | Buy |
| 2025-11-11 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-10-23 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-21 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-21 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-21 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-09-18 | Guggenheim | Initiate | Buy |
| 2025-09-12 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-09-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-09-09 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-09-09 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-09-08 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-09-04 | JMP Securities | Initiate | Market Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.01
- Revenue Estimate
- 5.108M
- Revenue Q2Q
- N/A
- EPS Q2Q
- -23.05%
- Number of Analysts
- 18
Next Earnings Revisions
Revenue (1 Month)
3.97%
Revenue (3 Months)
-15.99%
EPS (1 Month)
-0.19%
EPS (3 Months)
-3.89%
Next Earnings Summary
IDYA is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -1.01 USD and the consensus revenue estimate is 5.11M USD.
The next earnings revenue estimate has been revised downward by 15.99% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 23.385M -54.08% | 7M -70.07% | 218.71M 3,024.43% | 42.554M -80.54% | 128.11M 201.05% | 229.44M 79.10% | 611.62M 166.57% | 1.055B 72.49% | 1.59B 50.71% | 2.021B 27.11% | 2.496B 23.50% | |
| EBITDA YoY % growth | -131.953M -118.47% | -324.588M -145.99% | -156.613M 51.75% | -407.537M -160.22% | -364.87M 10.47% | -253.127M 30.63% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -134.429M -115.09% | -326.975M -143.23% | -159.313M 51.28% | -399.805M -150.96% | -356.325M 10.88% | -272.143M 23.63% | -61.347M 77.46% | 248.68M 505.37% | 657.97M 164.59% | 995.86M 51.35% | 1.313B 31.85% | |
| Operating Margin | -574.85% | -4,671.07% | -72.84% | -939.52% | -278.14% | -118.61% | -10.03% | 23.57% | 41.38% | 49.28% | 52.60% | |
| EPS YoY % growth | -1.97 -41.73% | -3.30 -67.51% | -1.31 60.30% | -4.04 -208.04% | -3.69 8.50% | -2.80 24.16% | -0.47 83.38% | 2.40 615.12% | 6.02 151.17% | 8.68 44.18% | 11.14 28.39% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.01 -23.05% | -1.00 -13.68% | -1.04 -177.88% | -0.98 -4.16% | -0.92 8.64% | -0.88 11.62% | -0.85 18.22% | -0.68 30.70% | 0.36 138.73% | -0.64 28.01% | -0.63 25.23% | -0.56 17.62% |
| Revenue Q2Q % growth | 5.108M | 8.083M | 5.955M -97.13% | 16.207M 49.02% | 28.016M 448.47% | 33.874M 319.08% | 41.769M 601.41% | 62.876M 287.96% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | -103.052M -22.99% | -93.082M -6.16% | -104.898M -194.99% | -94.47M -2.83% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -99.578M -18.00% | -98.505M -10.68% | -102.886M -194.87% | -99.324M -5.03% | -80.113M 19.55% | -75.468M 23.39% | -75.53M 26.59% | -67.8M 31.74% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-28.82%
EPS Next 5 Year
30.81%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
5.54%
Revenue Next 5 Year
40.14%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-13.89%
EBIT Next 5 Year
N/A
IDEAYA BIOSCIENCES INC / IDYA Forecast FAQ
Can you provide the upcoming earnings date for IDEAYA BIOSCIENCES INC?
IDEAYA BIOSCIENCES INC (IDYA) will report earnings on 2026-05-04.
What are the consensus estimates for IDYA stock next earnings?
The consensus EPS estimate for the next earnings of IDEAYA BIOSCIENCES INC (IDYA) is -1.01 USD and the consensus revenue estimate is 5.11M USD.
Can you provide the analyst count for IDEAYA BIOSCIENCES INC stock?
The number of analysts covering IDEAYA BIOSCIENCES INC (IDYA) is 25.